Back to search results

A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)

IsraelRecruitingPHASE1, PHASE2

Conditions

Small Cell Lung Cancer Extensive Stage

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Providence Medical Foundation ( Site 0124), Santa Rosa, California, United States

    Study coordinator · 707-521-3830

  • Orlando Health Cancer Institute ( Site 0108), Orlando, Florida, United States

    Study coordinator · 321-841-1869

  • Saint Elizabeth Medical Center Edgewood ( Site 0112), Edgewood, Kentucky, United States

    Study coordinator · 859-301-4000

  • Washington University School of Medicine ( Site 0134), St Louis, Missouri, United States

    Study coordinator · 314-747-1171

  • John Theurer Cancer Center at Hackensack University Medical Center ( Site 0101), Hackensack, New Jersey, United States

    Study coordinator · 551-996-5955

  • Providence Cancer Institute, Franz Clinic - Eastside ( Site 0107), Portland, Oregon, United States

    Study coordinator · 503-215-5696

  • Avera Cancer Institute- Research ( Site 0104), Sioux Falls, South Dakota, United States

    Study coordinator · 605-322-6900

  • The University of Tennessee Medical Center ( Site 0120), Knoxville, Tennessee, United States

    Study coordinator · 865-305-8780

  • Lt. Col. Luke Weathers, Jr. VA Medical Center ( Site 0133), Memphis, Tennessee, United States

    Study coordinator · 901-351-3673

  • SCRI Oncology Partners ( Site 7000), Nashville, Tennessee, United States

    Study coordinator · 844-482-4812

  • Houston Methodist Hospital - Houston Methodist Neal Cancer Center ( Site 0113), Houston, Texas, United States

    Study coordinator · 646-407-2086

  • University of Virginia Health System ( Site 0122), Charlottesville, Virginia, United States

    Study coordinator · 434-924-4251

  • CEMIC ( Site 1903), Caba., Buenos Aires, Argentina

    Study coordinator · +5491160006609

  • Hospital Austral ( Site 1901), Pilar, Buenos Aires, Argentina

    Study coordinator · +54911 38018573

  • Sanatorio Parque ( Site 1900), Rosario, Santa Fe Province, Argentina

    Study coordinator · +5493416955611

  • FALP ( Site 0200), Santiago, Region M. de Santiago, Chile

    Study coordinator · 56224205098

  • Pontificia Universidad Catolica de Chile ( Site 0202), Santiago, Region M. de Santiago, Chile

    Study coordinator · +56934271024

  • Bradfordhill ( Site 0201), Santiago, Region M. de Santiago, Chile

    Study coordinator · 56229490970

  • Beijing Cancer Hospital ( Site 1604), Beijing, Beijing Municipality, China

    Study coordinator · 010-88121122

  • Southern Medical University Nanfang Hospital ( Site 1608), Guangzhou, Guangdong, China

    Study coordinator · +86 13632102245

  • Jiangmen Central Hospital ( Site 1611), Jiangmen, Guangdong, China

    Study coordinator · +86 13702282382

  • The First Affiliated Hospital of Nanchang University ( Site 1610), Nanchang, Jiangxi, China

    Study coordinator · +86079186319453

  • Shanghai East Hospital ( Site 1600), Shanghai, Shanghai Municipality, China

    Study coordinator · 021-20334534

  • Sichuan Cancer hospital. ( Site 1609), Chengdu, Sichuan, China

    Study coordinator · 18180900912

  • The first Affiliated Hospital, Zhejiang University School of Medicine ( Site 1602), Hangzhou, Zhejiang, China

    Study coordinator · +8657187236560

  • Taizhou Hospital of Zhejiang Province ( Site 1601), Taizhou, Zhejiang, China

    Study coordinator · 0576-85199810

  • Universitaetsklinikum Jena ( Site 0403), Jena, Thuringia, Germany

    Study coordinator · +4936419324584

  • Rambam Health Care Campus ( Site 0602), Haifa, Israel

    Study coordinator · +97247772688

  • Sheba Medical Center ( Site 0601), Ramat Gan, Israel

    Study coordinator · +97235303030

  • Seoul National University Hospital ( Site 1402), Seoul, South Korea

    Study coordinator · 82-2-2072-3559

  • Severance Hospital Yonsei University Health System ( Site 1403), Seoul, South Korea

    Study coordinator · +82215991004

  • Asan Medical Center ( Site 1404), Seoul, South Korea

    Study coordinator · +82230103215

  • Samsung Medical Center ( Site 1401), Seoul, South Korea

    Study coordinator · 02-3410-1795

  • Hospital San Pedro ( Site 1004), Logroño, La Rioja, Spain

    Study coordinator · 941278760

  • Hospital Universitario Insular de Gran Canaria ( Site 1002), Las Palmas de Gran Canaria, Las Palmas, Spain

    Study coordinator · +34 928441738

  • Faculty of Medicine Siriraj Hospital ( Site 3000), Bangkoknoi, Bangkok, Thailand

    Study coordinator · +6624194488

  • Songklanagarind hospital ( Site 3001), Hat Yai, Changwat Songkhla, Thailand

    Study coordinator · +6674451469
Study leads

  • Medical Director

    Study Director

    Merck Sharp & Dohme LLC

View source on ClinicalTrials.gov(opens in a new tab)